HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) has been assigned an average recommendation of "Hold" from the six ratings firms that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $3.00.
Separately, HC Wainwright reissued a "neutral" rating and issued a $2.00 price objective on shares of HilleVax in a research report on Monday, March 31st.
Get Our Latest Stock Analysis on HilleVax
HilleVax Stock Up 0.5 %
Shares of HLVX stock traded up $0.01 on Friday, reaching $1.94. 444,520 shares of the stock were exchanged, compared to its average volume of 445,142. The stock has a market cap of $97.27 million, a P/E ratio of -0.63 and a beta of 0.86. The firm has a 50 day moving average of $1.69 and a two-hundred day moving average of $1.84. HilleVax has a 1-year low of $1.34 and a 1-year high of $16.31.
HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). On average, equities research analysts predict that HilleVax will post -2.64 EPS for the current fiscal year.
Institutional Trading of HilleVax
Several large investors have recently modified their holdings of HLVX. Jane Street Group LLC grew its stake in shares of HilleVax by 81.7% during the third quarter. Jane Street Group LLC now owns 79,039 shares of the company's stock valued at $139,000 after acquiring an additional 35,546 shares in the last quarter. Barclays PLC grew its stake in shares of HilleVax by 255.6% during the third quarter. Barclays PLC now owns 42,033 shares of the company's stock valued at $74,000 after acquiring an additional 30,213 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of HilleVax by 61.6% during the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after acquiring an additional 6,916 shares in the last quarter. Ieq Capital LLC grew its stake in shares of HilleVax by 71.1% during the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock valued at $47,000 after acquiring an additional 9,344 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of HilleVax during the fourth quarter valued at about $26,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.
About HilleVax
(
Get Free ReportHilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
